Chimeric live-attenuated vaccine against porcine circovirus
This technology provides a method for creating a safe, effective vaccine against Porcine Circovirus Type 2 (PCV2), a devastating virus in the swine industry. By swapping a specific gene from the harmful PCV2 virus into a harmless version of the virus (PCV1), researchers created a 'chimeric' virus that looks like the disease to an animal's immune system but lacks the ability to cause illness. This chimeric virus acts as a live-attenuated vaccine, triggering a strong immune response that protects pigs from wasting syndrome without the risks associated with using a weakened version of the actual pathogen.
What you could build
A live-attenuated injectable vaccine for piglets to prevent postweaning multisystemic wasting syndrome (PMWS), marketed to large-scale swine producers and veterinary pharmaceutical companies.
Who in Virginia should care
Virginia's significant swine production industry and the presence of major animal health veterinary research centers at Virginia Tech make this highly relevant.
Readiness: Prototype likely
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Xiang-Jin Meng, Martijn Fenaux, Patrick G. Halbur
- Granted
- December 17, 2019
- Status
- Granted patent
- Patent number
- 10507238
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.